In Vitro Diagnostics Market Size, Share, Growth and Forecast, 2025-2035

Reagent volumes and home tests reshape lab medicine

The global in vitro diagnostics (IVD) market was valued at USD 119.30 billion in 2025 and is projected to increase from USD 125.37 billion in 2026 to USD 196.01 billion by 2035, registering a CAGR of 5.09% during 2026–2035. Demand comes from hospital laboratories, independent reference labs, clinics, research centers and patients who test at home, all of whom rely on blood, urine, swab and tissue tests to detect disease and guide treatment. North America held the largest regional share, 40.0% in 2025, because high test volumes, broad insurance coverage and a dense network of reference labs support spending. Asia Pacific is the fastest-growing region at 6.28% a year, as China and India expand hospital laboratories and screening programs. The main change is the move of molecular testing closer to patients, with CLIA-waived PCR systems and the first over-the-counter test for three sexually transmitted infections cleared in the U.S. in 2025.

Which tests and products count toward market value?

The market counts manufacturer revenue from instruments and reagents used to examine samples taken from the human body, including blood, urine, saliva, swabs and tissue. It covers immunoassay, clinical chemistry, hematology and molecular platforms, plus microbiology, coagulation, urinalysis and rapid tests grouped under others. Buyers include hospitals, independent laboratories, physician clinics, research institutes and consumers who buy self-tests.

Reagents and consumables account for most value, because each installed analyzer consumes test kits for many years under reagent rental or supply contracts. The scope excludes imaging equipment, laboratory service fees charged to patients and research-only tools, and the value chain runs from assay developers and instrument makers through distributors to labs.

Reagents, immunoassays and hospitals lead test spending

Why do reagents earn most of the revenue?

Based on product, the market is categorized into instruments and reagents. Reagents led with a 68.0% share of 2025 value and also grow fastest at 5.28% a year. This lead reflects the razor-and-blade model, because labs often place analyzers under rental agreements and then buy assays, calibrators and controls for every test they run. As a result, reagent revenue rises with test volumes even when instrument sales slow.

Why does immunoassay lead while molecular grows faster?

Based on technology, the market is categorized into immunoassay, hematology, clinical chemistry, molecular diagnostics and others. Immunoassay led with a 30.0% share of 2025 value, because hormone, cardiac, infectious disease and tumor marker tests run on high-throughput analyzers. Molecular Diagnostics grows fastest at 6.01% a year, as PCR panels and next-generation sequencing move into routine oncology and infection testing.

Where are tests run and bought?

Based on end user, the market is categorized into hospital, home care setting, research institutes, clinics and independent laboratory. Hospital labs led with a 42.0% share of 2025 value, because emergency, inpatient and surgical care need fast results around the clock. Home Care Setting grows fastest at 7.01% a year, as regulators clear more self-tests for infections and chronic disease monitoring.

Chronic disease, infection control and faster results

How does chronic disease raise routine test volumes?

Diabetes, heart disease, kidney disease and cancer require repeated blood tests for diagnosis and long-term monitoring, which keeps clinical chemistry and immunoassay analyzers busy in every health system. Aging populations in North America, Europe, Japan and China add more patients who need regular glucose, lipid, kidney and cardiac marker panels. Because each patient returns for testing several times a year, reagent demand grows steadily. In turn, hospitals invest in automated lines and hematology analyzers to handle larger daily workloads.

Why does infectious disease testing keep growing?

Infections such as tuberculosis, HIV and hepatitis need accurate tests before treatment begins, which keeps molecular test demand high. The WHO reports that 8.2 million people were newly diagnosed with TB in 2023, the highest number since it began global monitoring in 1995. However, only 62% of pulmonary new and relapse cases were bacteriologically confirmed in 2023. As a result, rapid molecular tests and bacteriological confirmation remain priorities for ministries of health and donor programs.

Download Free Sample

How do faster point-of-care results change clinical decisions?

Clinicians want results during the same visit, which lets them start treatment before patients leave urgent care or a clinic. In January 2025, Roche received FDA clearance with CLIA waiver for cobas liat tests for chlamydia, gonorrhea and Mycoplasma genitalium, with results in 20 minutes or less. Because CLIA-waived systems can be run by staff with minimal training, PCR testing now reaches retail clinics and community health sites. This shift supports wider use of point-of-care testing across primary care.

Why do precision oncology and screening lift test value?

Cancer care increasingly depends on biomarker and genomic tests that select targeted therapies and track recurrence, and these tests carry higher prices than routine chemistry panels. Colorectal screening by stool DNA test, tumor gene expression profiling and blood-based residual disease tests are moving into standard practice in the U.S. Abbott announced that it completed its acquisition of Exact Sciences on March 23, 2026, adding Cologuard, Oncotype DX and Oncodetect to a large diagnostics portfolio. As a result, oncology adds value faster than test volumes.

Self-testing, syndromic panels and portfolio deals

Why is self-testing rising beyond COVID-19?

Consumers have become used to testing at home since the pandemic, and regulators now clear home tests for other infections. On March 28, 2025, the FDA granted marketing authorization to the Visby Medical Women's Sexual Health Test, the first home test for chlamydia, gonorrhea and trichomoniasis sold without a prescription. Visby announced that the test returns results in about 30 minutes. This rise gives the home care setting the fastest growth among end users through 2035.

How are syndromic panels changing infection workups?

Hospitals are shifting from single-pathogen tests toward syndromic PCR panels that check many respiratory, gastrointestinal or bloodstream pathogens from one sample. In September 2025, QIAGEN announced U.S. clearance of the QIAstat-Dx Rise, which runs up to 160 tests a day across eight modules with about one hour to result. Because panels shorten the path to the right antibiotic, labs use them to support stewardship programs and reduce repeat testing.

Download Free Sample

Where is the opening in tuberculosis and emerging markets?

Rapid molecular testing for tuberculosis, HIV and hepatitis in Asia, Africa and Latin America is a clear opening, because many patients are still diagnosed late or by older methods. WHO data show global TB notifications rose from 5.8 million in 2020 to 8.2 million in 2023. Companies that offer low-cost cartridges, durable instruments and local service can capture this growth as public programs scale case finding.

Can portfolio reshaping open room for focused players?

Large conglomerates are separating diagnostics units, which creates an opening for focused companies to invest and partner. BD completed the combination of its Biosciences and Diagnostic Solutions business with Waters on Feb. 9, 2026. Siemens Healthineers also said on its fiscal second-quarter 2026 results call that it is preparing to carve out its diagnostics business. In January 2025, bioMérieux also announced an agreement to acquire SpinChip Diagnostics and its 10-minute whole blood immunoassay platform.

Pricing pressure, rule changes and lab staff shortages

How does reimbursement pressure limit value growth?

Public and private payers keep cutting fees for routine laboratory tests, which squeezes hospital and reference lab budgets. Labs respond by consolidating suppliers, demanding lower reagent prices and running more tests on fewer platforms. As a result, value growth in clinical chemistry and hematology trails test volume growth. Manufacturers offset this pressure with automation, service contracts and premium assays, although price competition in tenders stays intense in Europe and China.

Why does regulatory change create uncertainty for labs?

Rules for laboratory-developed tests have shifted sharply in the U.S., which makes long-term planning harder for labs and test developers. A federal court vacated the FDA rule on these tests on March 31, 2025, and the FDA rescinded its 2024 final rule in September 2025. However, tighter conformity requirements in Europe still add cost and delay for assay makers. Companies must therefore fund regulatory teams that track several regimes at once.

How do laboratory staff shortages slow adoption?

Many hospitals and reference labs report shortages of trained laboratory scientists and technicians, which limits how many tests they can run each day. Older staff are retiring faster than training programs replace them, especially in rural areas. These gaps delay the launch of new assays that need manual steps. In turn, buyers favor fully automated systems, although such systems require large capital budgets that smaller labs cannot always fund.

Why does post-pandemic demand normalization weigh on molecular sales?

COVID-19 testing created a sharp spike in molecular and antigen test revenue during 2020 to 2022, followed by a steep decline. Many labs still hold excess PCR capacity, which slows new instrument orders in some regions. Manufacturers have therefore shifted their molecular menus toward respiratory panels, sexually transmitted infections and oncology. This transition takes time, because each new assay needs clinical studies and regulatory clearance before launch.

U.S. lab volumes lead as Asian testing capacity grows

North America leads on test volumes and reference labs

North America held a 40.0% share of 2025 value and grows at 4.68% a year through 2035. The U.S. leads spending, because large reference labs such as Quest Diagnostics process high volumes of chemistry, immunoassay and molecular tests. New CLIA-waived and over-the-counter clearances in 2025 extend testing into retail clinics and homes. However, fee cuts for routine tests hold down value growth for older assay menus.

Europe balances tenders and regulatory cost

Europe held a 27.0% share of 2025 value and grows at 4.38% a year, the slowest pace among the five regions. Germany, France, Italy, Spain and the U.K. account for most demand, with hospital groups buying through competitive tenders. As a result, European laboratories run high volumes at lower prices per test, while manufacturers carry added conformity costs for each assay.

Download Free Sample

Asia Pacific grows on hospital lab expansion

Asia Pacific held a 24.0% share of 2025 value and is the fastest-growing region at 6.28% a year. China and India are building hospital laboratories and screening programs, while Japan and South Korea keep high per-capita test use. Local manufacturers compete hard on price in China through volume-based procurement. In turn, global suppliers focus on premium immunoassay and molecular menus.

Latin America relies on private laboratory chains

Latin America held a 5.5% share of 2025 value and grows at 5.58% a year through 2035. Brazil and Mexico account for most demand, where private laboratory chains run large networks of collection centers. Currency swings and public budget limits slow the purchase of new analyzers.

Middle East and Africa build testing capacity

The Middle East & Africa held a 3.5% share of 2025 value and grows at 5.78% a year. Gulf states invest in hospital laboratories and genomic programs through public health plans. In much of Africa, donor-funded programs drive demand for HIV and tuberculosis tests.

Download Free Sample

Clearances and portfolio deals from 2025 to 2026

Automation and rapid PCR shorten time to result

• CLIA-waived PCR systems such as cobas liat deliver molecular results in about 20 minutes at clinics with minimal staff training.
• Syndromic PCR panels detect many pathogens from one sample, and systems such as QIAstat-Dx Rise run up to 160 tests a day in about 1 hour each.
• Total laboratory automation links sample sorting, analyzers and storage on one track, which raises daily throughput with fewer staff.
• Whole blood immunoassay analyzers measure cardiac markers such as troponin at the bedside in about 10 minutes.
• Blood-based cancer tests detect tumor DNA for screening and recurrence monitoring, which moves oncology testing toward simple blood draws.

Platform makers compete on menus and installed base

Competition in in vitro diagnostics rests on installed analyzers, broad test menus and long reagent contracts. Roche, Abbott, Siemens Healthineers and Danaher compete across immunoassay, clinical chemistry and molecular testing, and they win hospital and reference lab contracts through automation and service. bioMérieux and QIAGEN focus on microbiology and syndromic molecular panels, while Bio-Rad Laboratories leads in quality controls and blood typing. Quidel Corporation competes in rapid tests for respiratory infections, and Agilent Technologies supplies pathology and companion test products. Quest Diagnostics is both a large buyer of reagents and a provider of laboratory services. BD moved its diagnostic solutions business to Waters in February 2026. Because labs rarely switch platforms, suppliers gain share mostly through new menus and acquisitions.

Companies profiled and their roles in this market

Recurring reagent sales carry value through 2035

Credence Research's view is that recurring reagent sales will carry most of the value growth in in vitro diagnostics through 2035. Immunoassay and clinical chemistry keep the volume base in hospitals and reference labs, but molecular testing adds value faster as syndromic panels and cancer tests spread. Home and point-of-care testing gains share as regulators clear more self-tests and CLIA-waived systems. Portfolio deals in 2026 show that owners now value focused diagnostics units. Suppliers with large installed bases and broad menus are best placed to grow.

Test volumes and reagent prices anchor the model

The report uses 2025 as the base year and forecasts market value to 2035, with growth rates stated for 2026–2035. Market values come from the Credence Research market model, which combines test volumes by technology, installed instruments and average reagent prices by region and end user. Splits by product, technology, end user and region are Credence Research estimates. Sources used include FDA announcements, WHO tuberculosis data, a hospital association news report and company press releases. No primary interviews or surveys were used to build the estimates in this report.

Decentralized testing gains share by 2035

By 2035, the market reaches USD 196.01 billion, with reagents still providing most of the value. Molecular testing gains share as respiratory, sexually transmitted infection and cancer panels move into routine care. Home testing grows fastest among end users, supported by over-the-counter clearances. Asia Pacific adds capacity as China and India expand hospital labs, while North America remains the largest region. Automation helps labs cope with staff shortages, and suppliers keep reshaping portfolios to focus on faster-growing menus.

Note: The depth of individual sections depends on data availability for this market. Volume, capacity, trade and other unit-based metrics are included where applicable.